Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Assess the Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases

NCT07523282 is registered in ClinicalTrials.gov with Shenzhen MagicRNA Biotechnology Co., Ltd as lead sponsor.

NCT NCT07523282
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07523282 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Assess the Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
Lead sponsor
Shenzhen MagicRNA Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 31, 2026
Completion date
June 30, 2028
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune disease, systemic lupus erythematosus, systemic sclerosis (ssc)